Luminex Corporation (NASDAQ:LMNX) Earns Daily Media Sentiment Rating of 0.12
News stories about Luminex Corporation (NASDAQ:LMNX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Luminex Corporation earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 46.8489601151453 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Harley-Davidson, Inc. (HOG) Shares Sold by Fifth Third Bancorp (techdeezer.com)
- Harley-Davidson Inc. (HOG) Is Sinking After Shipment Guidance Cut (nolopodrasdejardever.com)
- Luminex Corporation Second Quarter Earnings Release Scheduled for August 7, 2017 (finance.yahoo.com)
- Zacks Investment Research Upgrades Luminex Corporation (LMNX) to “Buy” (americanbankingnews.com)
- ETFs with exposure to Luminex Corp. : July 14, 2017 (finance.yahoo.com)
LMNX has been the subject of a number of research reports. TheStreet upgraded Luminex Corporation from a “c+” rating to a “b-” rating in a research report on Friday, May 19th. Zacks Investment Research upgraded Luminex Corporation from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a research report on Monday. ValuEngine upgraded Luminex Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, May 11th. Finally, Jefferies Group LLC upped their price objective on Luminex Corporation from $20.00 to $21.00 and gave the company a “hold” rating in a research report on Tuesday, May 2nd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. Luminex Corporation presently has a consensus rating of “Hold” and an average price target of $21.67.
Shares of Luminex Corporation (LMNX) opened at 20.65 on Wednesday. The firm has a 50-day moving average price of $20.80 and a 200-day moving average price of $19.64. The stock has a market cap of $907.07 million, a PE ratio of 64.13 and a beta of 0.29. Luminex Corporation has a 12 month low of $17.64 and a 12 month high of $23.75.
Luminex Corporation (NASDAQ:LMNX) last released its quarterly earnings data on Monday, May 1st. The medical instruments supplier reported $0.28 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.12. The business had revenue of $77.80 million during the quarter, compared to analyst estimates of $74.25 million. Luminex Corporation had a return on equity of 5.48% and a net margin of 5.00%. The company’s revenue was up 23.5% on a year-over-year basis. During the same quarter last year, the business posted $0.29 EPS. Equities analysts forecast that Luminex Corporation will post $0.52 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, July 14th. Shareholders of record on Friday, June 23rd were paid a dividend of $0.06 per share. The ex-dividend date was Wednesday, June 21st. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.16%. Luminex Corporation’s payout ratio is currently 75.00%.
In other Luminex Corporation news, Director G Walter Loewenbaum II sold 25,000 shares of Luminex Corporation stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $20.23, for a total transaction of $505,750.00. Following the completion of the transaction, the director now owns 738,896 shares in the company, valued at approximately $14,947,866.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 75,000 shares of company stock valued at $1,527,500 in the last quarter. Company insiders own 6.90% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/07/19/luminex-corporation-nasdaqlmnx-earns-daily-media-sentiment-rating-of-0-12.html.
About Luminex Corporation
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.